Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy

(2012) J. S. Orange et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

(2012) Richard L. Wasserman et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

(2012) Richard L. Wasserman   JOURNAL OF CLINICAL IMMUNOLOGY

Primary Immunodeficiency Diseases Worldwide: More Common than Generally Thought

(2012) Ahmed Aziz Bousfiha et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model

(2012) David W. Kang et al.   Drug Delivery and Translational Research

Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a Practical approach

(2011) S. Jolles et al.   ADVANCES IN THERAPY

Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy

(2011) S. Jolles et al.   CLINICAL IMMUNOLOGY

Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency

(2011) Richard L. Wasserman et al.   CLINICAL PHARMACOKINETICS

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

(2011) Richard L. Wasserman et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G

(2011) Melvin Berger et al.   SOUTHERN MEDICAL JOURNAL

Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century

(2010) Meredith L. Moore et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies

(2010) Marc J. Meth et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Hyaluronidase allergy: A rare cause of periorbital inflammation

(2010) Kate Borchard et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies

(2010) R. Gustafson et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions

(2010) A. GARDULF et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease

(2010) R. L. Wasserman et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

(2010) Jordan S. Orange et al.   CLINICAL IMMUNOLOGY

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

(2010) John B. Hagan et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency

(2010) E. Knight et al.   JOURNAL OF CLINICAL PATHOLOGY

Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models

(2010) C. B. Thompson et al.   MOLECULAR CANCER THERAPEUTICS

Gammaglobulina subcutánea en inmunodeficiencia común variable. Primera experiencia en España

(2009) M. Maroto Hernando et al.   ANALES DE PEDIATRIA

Subcutaneous immunoglobulin: opportunities and outlook

(2009) S. Misbah et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers

(2009) George Harb et al.   CURRENT MEDICAL RESEARCH AND OPINION

Primary immunodeficiencies: 2009 update

(2009) Luigi D. Notarangelo et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients with Advanced Illness

(2009) Jay R. Thomas et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Recombinant Human Hyaluronidase-Enabled Subcutaneous Pediatric Rehydration

(2009) C. H. Allen et al.   PEDIATRICS

Intravenous immunoglobulin: Adverse reactions and management

(2008) Francisco A. Bonilla   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY